Rezvilutamide is primarily used in the treatment of prostate cancer, particularly in cases of non-metastatic castration-resistant prostate cancer (nmCRPC). It functions as an androgen receptor inhibitor, helping to block the activity of male hormones that can promote the growth of prostate cancer cells. Due to its high selectivity and strong binding affinity to the androgen receptor, it effectively suppresses tumor progression and delays the onset of metastasis. Clinical studies have shown that rezvilutamide can significantly improve metastasis-free survival when used in combination with androgen deprivation therapy. Its favorable safety profile and once-daily dosing make it a suitable option for long-term management of high-risk patients.